Printer Friendly

LA JOLLA PHARMACEUTICAL CO. ANNOUNCES SECOND GENERATION MOLECULE TO TREAT LUPUS

 SAN DIEGO, March 31 /PRNewswire/ -- La Jolla Pharmaceutical Co. announced today that it has developed a more potent second generation drug candidate to treat Systemic Lupus Erythematosus (SLE) based on its proprietary "Tolerance Technology(TM)."
 This new drug candidate carries the designation LJP-394 and has been named Renatol(TM) (now in trademark registration). In animal tests, it is an order of magnitude or more effective than earlier molecules. It will now move from R&D to manufacturing scale-up and toxicology trials. Increased potency and efficacy should lead to lower doses in patients and an improved efficacy/safety profile.
 Lupus is a life-threatening disease which afflicts more than 500,000 in the United States and Europe. Current treatment is considered very inadequate. The new drug candidate arrests the synthesis of antibodies to double stranded DNA, a hallmark of the disease. These antibodies are considered to be responsible for the serious and debilitating chronic kidney disease of lupus patients. The worldwide market is estimated to exceed $1 billion.
 "We are now well positioned to move toward toxicology and the critical clinical trial phase with our first major product. The progress in our biology and chemistry programs which led up to Renatol(TM) also gives it a good prognosis to be cost-effective," said Joseph Stemler, president and chief executive officer.
 La Jolla Pharmaceutical Co. was founded in 1989 to develop products based on its proprietary "toleragen technology" to treat antibody-mediated diseases. The company is privately held and is headquartered in San Diego.
 -0- 3/31/93
 /CONTACT: Andrew Wiseman, Ph.D. of La Jolla Pharmaceutical Co., 619-452-6600/


CO: La Jolla Pharmaceutical Co. ST: California IN: MTC SU:

LS-KJ -- SD009 -- 1753 03/31/93 18:01 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 31, 1993
Words:283
Previous Article:NEW YORK STOCK EXCHANGE CLOSING, WEDNESDAY, MARCH 31 /PRN/
Next Article:STERLING FINANCIAL CORP. PURCHASES FORMER FREDERICK & NELSON BUILDING
Topics:


Related Articles
LA JOLLA PHARMACEUTICAL LAUNCHES INFLAMMATION PROGRAM
LA JOLLA PHARMACEUTICAL CO. FILES IND ON NEW DRUG FOR LUPUS
LA JOLLA PHARMACEUTICAL STARTS HUMAN CLINICAL TRIALS
LA JOLLA PHARMACEUTICAL COMPLETES PHASE I CLINICAL TRIAL OF DRUG FOR LUPUS
RESULTS OF A UCSD LUPUS STUDY SPONSORED BY LA JOLLA PHARMACEUTICAL COMPANY PRESENTED AT AMERICAN COLLEGE OF RHEUMATOLOGY
LA JOLLA PHARMACEUTICAL SIGNS $40 MILLION EUROPEAN PARTNERSHIP
LA JOLLA PHARMACEUTICAL COMPANY PHASE II TRIALS SHOW SAFETY AND POSITIVE DOSE RESPONSE
La Jolla Pharmaceutical Initiates Phase II/III Clinical Trial for Lupus Drug
La Jolla Pharmaceutical Identifies Disease Target in Severe Blood Clotting Disorder

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters